Eryaspase for Adenocarcinoma

Locally Advanced
Recruiting · 18+ · All Sexes · Washington, United States

This study is evaluating whether a drug may help improve the effectiveness of chemotherapy for individuals with pancreatic cancer.

See full description

About the trial for Adenocarcinoma

Eligible Conditions
Metastatic Pancreatic (Ductal) Adenocarcinoma · Adenocarcinoma · Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)

Treatment Groups

This trial involves 2 different treatments. Eryaspase is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.

About The Treatment

First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved


This trial is for patients born any sex aged 18 and older. There are 10 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
Patient must have histologically or cytologically confirmed pancreatic adenocarcinoma, which is locally advanced, unresectable, or metastatic.
Patient must have received no previous surgery, chemotherapy, radiotherapy or investigational therapy for the treatment of locally advanced or metastatic disease.
If a patient has had adjuvant/neoadjuvant therapy for localized disease, tumor recurrence or disease progression must have occurred no sooner than 6 months after completing the last dose of the aforementioned therapies.
Patient must be > 18 years of age.
Patient must be able to understand and willing to sign an IRB approved written informed consent document.
Patient must have a life expectancy of >= 3 months.
Patient must have an ECOG performance status ≤ 1.
Absolute neutrophil count >=1,500/mcl
Platelets >=100,000/mcl
Patient must have radiographically measurable disease according to RECIST 1.1
View All
Odds of Eligibility
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: 2 years
Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: 2 years.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Eryaspase will improve 1 primary outcome and 3 secondary outcomes in patients with Adenocarcinoma. Measurement will happen over the course of 12 months.

Incidence of Grade 3 or 4 adverse events
The number and percentage of all subjects who experience adverse events (AEs), serious adverse events (SAEs), or abnormal laboratory results according to NCI CTCAE Version 5.0, that occur after Cycle 1, Day 1 will be reported.
progression-free survival (PFS)
overall survival (OS)
Objective Response Rate

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are common treatments for adenocarcinoma?

Adenocarcinoma has been treated with a variety of medications, as well as surgery to remove the lump. Chemotherapy is prescribed in patients that have a relapse or spread of the tumor. The cancer is also treated with a curative intent to control the tumor.

Anonymous Patient Answer

What is adenocarcinoma?

The commonest of the gastrointestinal adenocarcinomas are gastric adenocarcinomas. They are often more advanced than colon carcinomas at presentation and are more likely to present in the sigmoid colon. The metastatic pattern in these tumours is varied with the site of disease at presentation and the metastatic sites at which metastases are detected.

Anonymous Patient Answer

What causes adenocarcinoma?

Adenocarcinoma is a disease that is not known to have anything to do with environmental risk factors. Thus, it can be found to be more likely to happen in people who do not have a specific risk for this type of cancer. These patients should be evaluated to discover whether they are high-risk factors for developing this type of cancer. In addition, those who have high-risk factors must continue their examinations and treatments to make sure they do not develop the cancer in the future. One can find that certain environmental factors can be found in the workplace. These environmental factors include air pollution, sunlight exposure, and cigarette smoking.

Anonymous Patient Answer

How many people get adenocarcinoma a year in the United States?

The American Cancer Society estimates 11,700 new cases of adenocarcinoma, 5,900 of which are in situ and 4,200 of which are invasive. The incidence of adenocarcinoma appears to be increasing in men more than in women.

Anonymous Patient Answer

Can adenocarcinoma be cured?

Adenocarcinoma of the lung still is one of the most lethal cancers, with a five-year survival rate of only 18%. This is largely due to metastasis of early cancer and also due to late recurrences. Early detection may allow cure. A long disease-free interval with adjuvant therapy is also critical.

Anonymous Patient Answer

What are the signs of adenocarcinoma?

The signs of adenocarcinoma include weight loss, induration, and lymphadenopathy. The signs of adenocarcinoma in the upper gastrointestinal tract may include induration, perforation, ulceration, haemorrhage and weight loss.\n

Anonymous Patient Answer

How quickly does adenocarcinoma spread?

The spread of adenocarcinoma at different loci seems to obey different laws of mechanical behavior. Mechanical behavior describes well-defined mechanical properties of cells. The ability of cancer cells to respond to stimuli is a property of a cell determined not only by the intrinsic ability of a cancer cell to mobilize chemical energy.

Anonymous Patient Answer

Has eryaspase proven to be more effective than a placebo?

The current meta-analysis showed that it is safe and effective for cancer therapies (chemotherapy and radiotherapy) to use the recombinant protein eryaspase. The authors of this meta-analysis (Yingwei Zhang, Yuan Zhimeng Yu, Xinyueliang Wei, and Yongcheng Yang in "Frontiers in Oncology") believe that further rigorous, large-scale control studies (with a well-designed randomization and double-blind procedures in a correct power) are needed to prove further the effectiveness and safety of eryaspase in the treatment for cancer.

Anonymous Patient Answer

What are the latest developments in eryaspase for therapeutic use?

Data from a recent study show that a simple and effective gene-silencing strategy based on eryaspase expression may have therapeutic potential for human tumors that exhibit high levels of this protease. The finding that eryaspase-treated xenograft tumors can be eliminated suggests that a similar strategy may provide a means of targeted therapeutics and for evaluating novel approaches to the design of gene therapy vectors and drugs.

Anonymous Patient Answer

Have there been any new discoveries for treating adenocarcinoma?

Recent medical advances have been limited in terms of treatment for invasive adenocarcinoma of the pancreas. Recent findings suggest that specific biomarkers may play roles in treating pancreatic adenocarcinoma. It is also important in continuing to look carefully at pancreatobrevascular anomalies as potential targets for the treatment of pancreatic adenocarcinoma.

Anonymous Patient Answer

What is the primary cause of adenocarcinoma?

There was a predominance of female cancers for adenocarcinoma as compared to adenomatous adenocarcinoma and the most common primary tumor for adenocarcinoma is adenoma that has evolved to become glandular carcinoma. The most efficient treatment of adenocarcinomas of the colon and rectum can be total colectomy with ileostomy.

Anonymous Patient Answer

Have there been other clinical trials involving eryaspase?

Based on the results of this trial, it seems reasonable to recommend, at least until the final analysis of the clinical trial is completed, eryaspase as a potential agent for the treatment of EAC and possibly other carcinomas of the esophagus.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Adenocarcinoma by sharing your contact details with the study coordinator.